Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicentre, Open-Label Study to Evaluate the PK, Safety, and Tolerability of a Single IV Dose of Rezafungin in Paediatric Subjects, Receiving Systemic Antifungals as Prophylaxis for IFI or to Treat a Suspected or Confirmed FI

NCT05534529 is registered in ClinicalTrials.gov with Mundipharma Research Limited as lead sponsor.

NCT NCT05534529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05534529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicentre, Open-Label Study to Evaluate the PK, Safety, and Tolerability of a Single IV Dose of Rezafungin in Paediatric Subjects, Receiving Systemic Antifungals as Prophylaxis for IFI or to Treat a Suspected or Confirmed FI
Lead sponsor
Mundipharma Research Limited
Phase
Phase 1
Overall status
Terminated
Start date
September 13, 2023
Completion date
October 14, 2024
Enrollment
32 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

invasive fungal infections